Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 5/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125700 | 0.88 | ALDH1A1 (0.38) | NFE2L2NAMPT | |
| SCHEMBL4125903 | 0.88 | NAMPT (0.38) | SLC40A1NAMPTKAT6A | |
| SCHEMBL4119401 | 0.88 | KAT6A (0.44) | AKR1C3MEP1BGAAMTNR1BKAT6A | |
| SCHEMBL4132234 | 0.87 | ATM (0.38) | NPC1NAMPTKAT6A | |
| SCHEMBL4125873 | 0.86 | CYP1A2 (0.33) | NPC1NAMPTAKR1C3 | |
| SCHEMBL4120137 | 0.85 | LIPG (0.32) | NAMPT | |
| SCHEMBL4137731 | 0.85 | NFE2L2 (0.38) | NFE2L2NPC1GLO1SLC40A1NAMPT | |
| SCHEMBL4117665 | 0.85 | LIPG (0.34) | NAMPT | |
| SCHEMBL4120230 | 0.84 | NAMPT (0.38) | GLO1SLC40A1NAMPT | |
| SCHEMBL4120645 | 0.84 | NFE2L2 (0.41) | NFE2L2NPC1GLO1SLC40A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NFE2L2 2670/4885NPC1 53/4885GLO1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.